- Ongoing, recruitingTherapeutic exploratory (Phase II)
BYLieve: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients withPIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments.
This study looks at new drug combinations for advanced breast cancer. It's for people whose cancer has a specific change (PIK3CA mutant) and has grown despite previous treatments. Researchers want to see if the new treatments can help people live longer without their cancer getting worse.
For: Adult patients with PIK3CA mutant · HR-positive · HER2-negative advanced breast cancerDenmark · Italy - AuthorisedTherapeutic confirmatory (Phase III)
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
This study, OPTIMA YOUNG, is for younger women with a common type of early breast cancer. It looks at the best way to treat this cancer to stop it from coming back, by comparing different medications and how well they work.
Poland · France · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.
This study looks at new ways to treat advanced breast cancer that has spread. It's for women with a specific type of hormone-positive breast cancer. Researchers are comparing two different drug combinations to see which works best at stopping the cancer from growing.
For: Metastatic Breast Cancer HR+ · HER2-France - AuthorisedTherapeutic exploratory (Phase II)
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
This study is looking at a new way to treat prostate cancer that has spread. It compares two different drug combinations to see which is better at stopping the cancer from growing for at least four months.
For: prostate cancerItaly